Skip to main content

Advertisement

Table 2 Correlation between the p53R2 expression and clinicopathological variables in NPC patients

From: p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma

Variable Expression of p53R2
All cases Low High P value
Gender     0.217
 Female 57 39 (68.4%) 18 (31.6%)  
 Male 144 85 (59.0%) 59 (41.0%)  
Age     0.593
 ≤45.89a 104 66 (63.5%) 38 (36.5%)  
 >45.89 97 58 (59.8%) 39 (40.2%)  
Clinical stage     0.450
 I-II 39 22(56.4%) 17 (43.6%)  
 III-IV 162 102(63.0%) 60 (37.0%)  
T stage     0.043
 T1 + T2 64 33 (51.6%) 31 (48.4%)  
 T3 + T4 137 91 (66.4%) 46 (33.6%)  
N stage     0.469
 N0 28 19 (67.9%) 9 (32.1%)  
 N1 + N2 + N3 173 105 (60.7%) 68 (39.3%)  
Therapyb     0.205
 Regimen 1 50 34 (68.0%) 16 (32.0%)  
 Regimen 2 72 46 (63.9%) 26 (36.1%)  
 Regimen 3 31 14 (45.2%) 17 (54.8%)  
 Regimen 4 48 30 (62.5%) 18 (37.5%)  
Relapse     0.543
 Yes 30 20 (66.7%) 10 (33.3%)  
 No 171 104 (60.8%) 67 (39.2%)  
  1. amean age; bRegimen 1, radiation therapy;Regimen 2, chemoradiotherapy; Regimen 3, induction + radiation therapy; Regimen 4, induction + chemoradiotherapy